BCL2 and neoplasm: By introducing WTP53, the mitochondrial pyruvate carrier (MPC) binding to pyruvate can be disrupted, which is realized by inducing BCL2 binding component 3 (Bbc3,also named PUMA) and inhibiting the uptake of pyruvate by mitochondria, thus promoting the survival of tumour cells and causing poor prognosis in HCC patients [326].